Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 842 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 842 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $80,991.98. Following the transaction, the senior vice president owned 3,700 shares in the company, valued at approximately $355,903. This trade represents a 18.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58.

Mirum Pharmaceuticals Trading Up 2.4%

Shares of Mirum Pharmaceuticals stock opened at $99.27 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The company has a market capitalization of $5.10 billion, a P/E ratio of -115.43 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $99.44. The company’s fifty day moving average is $78.36 and its two-hundred day moving average is $71.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MIRM shares. TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Citizens Jmp raised their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, December 19th. Finally, Leerink Partners set a $100.00 price objective on Mirum Pharmaceuticals in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.92.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Eventide Asset Management LLC raised its position in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after buying an additional 110,485 shares during the last quarter. Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock valued at $52,405,000 after acquiring an additional 65,951 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after purchasing an additional 672,118 shares during the period. Boone Capital Management LLC boosted its holdings in shares of Mirum Pharmaceuticals by 6.3% during the second quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock worth $32,643,000 after purchasing an additional 38,130 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares during the period.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
• Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
• Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
• Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.